Literature DB >> 24255085

Survival differences between organ preservation surgery and definitive radiotherapy in early supraglottic squamous cell carcinoma.

Hassan Arshad1, Vijayvel Jayaprakash, Vishal Gupta, David M Cohan, Dildeep Ambujakshan, Nestor R Rigual, Anurag K Singh, Wesley L Hicks.   

Abstract

OBJECTIVE: Single-modality treatment, either with organ preservation surgery (OPS) or definitive radiation (RT), is the treatment of choice for patients with early supraglottic squamous cell carcinoma (SGC). However, studies comparing the effectiveness of these 2 techniques are lacking. This study compares the survival outcomes in early SGC patients treated with OPS versus RT. STUDY
DESIGN: Secondary data analysis.
SETTING: Surveillance, Epidemiology and End Results database. SUBJECTS AND METHODS: This study included adult patients with early-stage (T1N0, T2N0) SGC undergoing single-modality treatment with either OPS (with or without neck dissection [ND]) or RT between 1988 and 2008. Survival analysis was used to compare the overall survival (OS) and disease-specific survival (DSS) between patients treated with OPS+ND, OPS alone, and RT.
RESULTS: A total of 2631 T1/T2 N0 SGC patients were identified, of whom 167 (6%) were treated with OPS+ND, 186 (7%) with OPS only, and 2278 patients (87%) with definitive RT only. In stage I (T1N0) SGC patients, a significantly better 5-year DSS was noted for both OPS+ND (81% vs 68%, hazard ratio [HR] = 0.61, P = .03) and OPS only (82% vs 68%, HR = 0.70, P = .05) when compared with definitive RT. For stage II (T2N0) patients, only OPS+ND resulted in a significantly better 5-year DSS (86% vs 60%, HR = 0.31, P < .001) when compared with patients treated with RT.
CONCLUSIONS: Patients with early SGC who underwent OPS+ND had better OS and DSS than patients undergoing RT alone. OPS+ND may be considered a viable and preferred treatment option in these patients.

Entities:  

Keywords:  definitive radiotherapy; disease-specific survival; organ preservation surgery; over survival; supraglottic squamous cell carcinoma

Mesh:

Year:  2013        PMID: 24255085     DOI: 10.1177/0194599813512783

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  5 in total

1.  Hypofractionation vs. conventional radiotherapy fractionation in the conservative treatment of T1 glottic cancer: a prospective cohort study.

Authors:  B G Salas-Salas; D J Domínguez-Nuez; R Cabrera; L Ferrera-Alayón; M Lloret; P C Lara
Journal:  Clin Transl Oncol       Date:  2019-06-01       Impact factor: 3.405

2.  Survival Outcomes in Patients with T2N0M0 (Stage II) Squamous Cell Carcinoma of the Larynx.

Authors:  Danielle L Gainor; Emily Marchiano; Emily Bellile; Matthew E Spector; Jeremy M G Taylor; Gregory T Wolf; Norman D Hogikyan; Mark E Prince; Carol R Bradford; Avraham Eisbruch; Francis Worden; Andrew G Shuman
Journal:  Otolaryngol Head Neck Surg       Date:  2017-06-13       Impact factor: 3.497

Review 3.  Potentials of lncRNA-miRNA-mRNA networks as biomarkers for laryngeal squamous cell carcinoma.

Authors:  Yan Lv; Yanhua Wang; Zhikai Zhang
Journal:  Hum Cell       Date:  2022-10-01       Impact factor: 4.374

Review 4.  Treatment of early stage Supraglottic squamous cell carcinoma: meta-analysis comparing primary surgery versus primary radiotherapy.

Authors:  Krupal B Patel; Anthony C Nichols; Kevin Fung; John Yoo; S Danielle MacNeil
Journal:  J Otolaryngol Head Neck Surg       Date:  2018-03-05

5.  En Bloc Resection of Supraglottic Carcinomas with Transoral Laser Microsurgery.

Authors:  Kerem Öztürk; Arin Öztürk; Göksel Turhal
Journal:  Turk Arch Otorhinolaryngol       Date:  2022-02-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.